Micell Technologies has announced that positive three-year clinical results from the DESSOLVE I and DESSOLVE II trials of its Mistent sirolimus-eluting stent (SES) with a biodegradable polymer were presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting (13–17 September, Washington, USA). The MiStent SES is designed to optimise vessel healing in patients with coronary artery disease
Normal endothelial function was maintained and there was minimal progression of late lumen loss through 18 months’ follow-up. In addition, the DESSOLVE studies had an overall target lesion revascularisation rate of 2% with no probable or definite stent thromboses related to MiStent SES at three-year follow-up.
“Three-year clinical outcomes of a unique sirolimus-eluting stent with fully absorbable polymer coating: long-term results from the DESSOLVE I and the DESSOLVE II clinical trials” was presented in poster and oral formats as part of the symposium “Metallic DES: Tomorrow’s technology.” John Ormiston (Mercy Angiography Unit, Auckland, New Zealand), who is a principal investigator in the DESSOLVE studies, presented the data.
He comments: “The MiStent SES is the sole product among the new generation of biodegradable polymer drug-eluting stent to sustain local drug delivery beyond the presence of the polymer, providing therapeutic sirolimus drug levels in the tissue surrounding the stent for up to nine months. Full elimination of the polymer by three months—without loss of antirestenotic drug effects—is different from any other drug-eluting formulation.”
